Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands

David Schaller¹*, Stefanie Hagenow², Holger Stark², Gerhard Wolber¹

¹ Molecular Design Lab, Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany, ² Institute of Pharmaceutical and Medicinal Chemistry, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany

* gerhard.wolber@fu-berlin.de

Abstract

In this study, we report a ligand-guided homology modeling approach allowing the analysis of relevant binding site residue conformations and the identification of two novel histamine H3 receptor ligands with binding affinity in the nanomolar range. The newly developed method is based on exploiting an essential charge interaction characteristic for aminergic G-protein coupled receptors for ranking 3D receptor models appropriate for the discovery of novel compounds through virtual screening.

Introduction

Virtual screening campaigns are typically classified into ligand-based approaches exploiting the similarity of molecules to already known active ligands, and structure-based approaches, where virtual screening models describe three-dimensional chemical interactions between molecules and the target structure [1]. A literature survey revealed that structure-based approaches are on average less successful in identifying highly active hits than ligand-based approaches [2]. However, if active lead compounds are identified, structure-based approaches hold the information for a subsequent rational optimization of interactions between ligand and target structure.

Although the amount of publicly available data for ligand-protein complexes is constantly increasing, structural data is not always available. In this situation researchers often rely on homology modeling, a method for generating the protein structure of interest based on closely related proteins with resolved crystal structures [3]. Including ligand information can aid the homology modeling process and decrease the level of uncertainty by evaluating homology models to enrich known actives from decoys in docking experiments and/or to allow docking poses that match data from mutational studies (often termed 'ligand-based', 'ligand-guided', 'ligand-steered' or 'ligand-supported homology modeling'). Especially G-protein coupled receptors (GPCRs) were extensively studied using such approaches including serotonin receptors [4], dopamine receptors [5], GABAR receptor [6] and neurokinin receptor 1 [7].
Most of these approaches heavily depend on scoring algorithms employed by docking programs to rank ligand poses and to estimate binding affinity [4–6]. However, docking scores often poorly correlate with binding affinity [8]. Also, searching for or optimizing a single homology model to bind a diverse set of ligands is arguable, since very different ligands might bind to or induce different protein conformations [9]. In contrast, Evers and Klebe avoided the use of docking scores by optimizing a homology model of the neurokinin receptor 1 to allow interactions with a single ligand that was extensively investigated including structure activity relationship of the ligand and mutational studies of the receptor to identify interacting amino acid chains [7]. Though, relying on mutational data can also be misleading, since mutations distant from the protein binding pocket can also drastically affect ligand binding [10].

In this study, we were interested if a single, yet important and reliable interaction can be exploited in a ligand-guided homology modeling workflow for the histamine H₃ receptor (H₃R) to gain structural knowledge about the binding site and to guide the selection of a homology model for subsequent virtual screening. We focused on an interaction of charged functional groups between ligands and aminergic GPCRs, which is well characterized and has been observed in multiple crystal structures of different GPCRs [11,12]. H₃R was selected as target for several reasons: (i) ligand data is publicly available, (ii) crystal structure is currently still missing, (iii) H₃R is an important drug target discussed for many severe diseases including Alzheimer’s disease, schizophrenia, Parkinson’s disease, narcolepsy, pain, and obesity among others [13,14] and (iv) a recent study of us revealed that H₃R and melanin-concentrating hormone receptor 1 can be inhibited by the same ligand which could be potentially used in obesity treatment [15]. In this project, 1000 homology models were generated and evaluated for allowing a charged interaction with a defined set of ligands. Best and worst performing models were structurally investigated and revealed the importance of distinct binding site residue conformations for proper ligand docking. The highest ranked model was used for a pharmacophore-based virtual screening campaign and led to the identification of two novel H₃R ligands with nanomolar affinity.

**Results and discussion**

**Ligand-guided homology modeling**

A template search revealed that the crystal structure of H₁R (3RZE [16]) does not show the highest sequence similarity to H₃R. Also, the extracellular loop 2 close to the orthosteric binding pocket is not resolved in the H₁R structure. Hence, homology modeling was performed with a multiple-template approach employing crystal structures of H₁R, muscarinic M₂ receptor (M₂R) and muscarinic M₃ (M₃R) receptor to generate 1000 homology models of H₃R with MODELLER 9.15 [17]. The average heavy atom RMSD of 1.2 Å was calculated with VMD 1.9.2 [18], whereat side chain heavy atoms were more flexible (1.6 Å) than backbone heavy atoms (0.4 Å). A set of 9 antagonists [19] (Table C in S1 File) was chosen to guide the selection of a homology model for later pharmacophore studies. We were specifically interested into this ligand series, since we found highly similar molecules active against the melanin-concentrating hormone receptor 1 (MCHR1) and dual antagonism of H₂R and MCHR1 might present a potential treatment option for obesity [15]. Additionally, these ligands are rather big showing Y-shaped conformations and thus should allow the selection of a homology model with an open binding pocket able to harbor diverse ligands. Subsequently, models were scored for presence of a charged interaction between the docked ligands and D₃,32 (numbering from Ballesteros-Weinstein numbering scheme [20]), that is known to be essential for ligand binding to aminergic GPCRs (Fig 1A) [11]. Docking and scoring have been performed twice to control for variations introduced by the docking algorithm (Fig B in S1 File). The highest
A ranked model achieved an average score of 0.835 in both docking experiments. This means that 83.5% of the docking poses allow for a charged interaction with D3.32. The predominant binding mode of docked ligands involves a charged interaction with D3.32, hydrogen bonds with D3.32, Y3.33, E5.46 and Y6.51 as well as several hydrophobic contacts (Fig 1B). Interestingly, we found that 25% of generated models retrieved a score of 0.1 or lower. From these, 7 models had a score of 0, which means that none of the docking poses was involved in the essential charged interaction.

Thus, we got interested what determinants could be used to distinguish highly scored models from poorly scored models. First, 10 best and 10 worst performing models were tested for geometric errors like phi-psi outliers and heavy atom clashes in MOE 2015 [24] as well as with homology modeling evaluation programs including VERIFY 3D [25], ERRAT [26] and PROVE [27]. However, none of the applied methods led to a successful discrimination (Fig C in S1 File). Next, we analyzed structural differences by comparing the side chain atoms average position of 10 best and 10 worst performing models (Fig 2). The atom with the highest difference (4.7 Å) in the average position is a carboxyl oxygen of E5.46 (Fig 2A). In the highly scored models E5.46 is pointing inside the binding pocket (Fig 2B). This is in line with the predominant docking pose that is involved in a hydrogen bond with E5.46. In contrast, poorly scored models show a conformation pointing outside the binding pocket. This conformation is also energetically unfavorable, since it is pointing toward the lipophilic membrane and no amino acid with opposite charge is present to compensate the negative charge. The importance of E5.46 in ligand binding is in agreement with mutational studies [28] and was already described in previous homology modeling studies for H3R [29,30]. Another atom with a rather high
difference in mean atom position (2.1 Å) is a distal side chain carbon of L_7.42. However, we were not able to draw a clear connection to the docking results.

**Virtual screening**

The highest scored homology model was used for a screening campaign to identify novel H₃R ligands. 10 diverse antagonists (Table A in S1 File) were docked into the homology model. Constraints were added to focus on docking poses involved in interactions with the negatively charged carboxyl-group of D_3.32 and E_5.46, since all inverse agonists contain at least one positively charged group. Docking poses with favorable interaction patterns were found for only 5 out of 10 compounds and additionally analyzed to agree with published structure activity relationship. Derivatives of CHEMBL1923737 (Fig 3, model A) tolerate differently sized pyridone analogues indicating a location of the pyridone group outside the relatively narrow orthosteric binding pocket [31]. The literature about CHEMBL2151197 (Fig 3, model B) has only sparse structure active relationship data [32]. However, later pharmacophore modeling motivated us to include this docking pose in virtual screening. Analogues of CHEMBL2387294 show that 1 positively charged group can be exchanged by hydrophobic groups without loss of activity [33]. Hence, a docking pose was chosen that is extending outside the receptor with more space for different interactions (Fig 3, model C). Data for CHEMBL1269844 report a decrease in activity when attaching the naphthalene moiety in an extending fashion [34]. Concordantly, such molecule would lead to clashes with the receptor in the selected binding mode (Fig D part A in S1 File). The preferred docking pose of the histamine analogue CHEMBL214312 (Fig D part B in S1 File) is complexed between D_3.32 and E_5.46 [35]. This binding mode agrees well with several previous docking studies of histamine [29,30]. Each of the 5 chosen binding poses is involved in an interaction with charged residues D_3.32 and E_5.46, which is agreement with the common binding mode of aminergic GPCRs involving D_3.32 and with the importance of E_5.46.
for proper ligand placement in our homology modeling approach (Fig 2) that is further supported by mutational data [28] and previous docking studies [29,30]. Docking poses of CHEMBL1923737 (model A), CHEMBL2151197 (model B) and CHEMBL2387294 (model C). Model A led to identification of compounds 3, 5, 6, 8, 9, model B to compounds 4, 7 and model C to compounds 1, 2, 10 (Fig 4, Table E in S1 File). Compounds 9 and 10 (model A and C) were removed from experimental testing due to insufficient purity as determined by LC-MS. Red arrows–hydrogen bond acceptors, green arrows–hydrogen bond donors, blue star–positive ionizable, yellow sphere–hydrophobic contact.

https://doi.org/10.1371/journal.pone.0218820.g003

---

**Fig 3. Virtual screening workflow results in 8 compounds out of 1.4 M for in-vitro validation.** Workflow for virtual screening using 3 different pharmacophores based on docking poses of CHEMBL1923737 (model A), CHEMBL2151197 (model B) and CHEMBL2387294 (model C). Model A led to identification of compounds 3, 5, 6, 8, 9, model B to compounds 4, 7 and model C to compounds 1, 2, 10 (Fig 4, Table E in S1 File). Only pharmacophore model C includes interactions with residue E5.46 whose conformation was found to be important for proper ligand docking in prior homology modeling selection. However, the 10 diverse inverse agonists used for this docking differ significantly from the shape of the Y-shaped compounds employed in ligand-guided homology modeling. Thus, it is not surprising that binding modes and interaction partners are to some extent different.
These pharmacophore models were used to screen a library of 1.4 M commercially available compounds (Enamine Ltd., Kyiv, Ukraine, www.enamine.net) resulting in almost 16,000 hits. The hits were docked into the respective minimized homology model and resulting docking poses were assessed for matching the previously screened pharmacophores. This procedure yielded 73 hits, which were visually inspected to identify hits complementing the receptor binding pocket surface. To broaden the chemical space of H₃R ligands, hits were also prioritized to cover positive ionizable head groups that are underrepresented or completely absent in the H₃R ligand data of the CHEMBL 20 database [40], i.e. terminal guanidino, 2,2,6,6-tetramethylpiperidino and secondary amino group (Fig 4). In total, 10 compounds were purchased for in-vitro testing. However, two compounds had to be excluded due to insufficient purity as determined by LC-MS (Table E in S1 File).

Two molecules (5 and 6) were found to bind H₃R in nanomolar concentration ranges (Fig 5). The identified binding mode indicates very similar interaction patterns including a charged interaction to D₃.₃₂, hydrogen bonds to D₃.₃₂ and Y₃.₃₃ as well as several hydrophobic contacts. Moreover, we observed pi-cation interactions to D₃.₃₂ and Y₃.₃₃. Compound 6 shows an additional pi-cation interaction to F₇.₃₉ which may contribute to its superior activity towards H₃R compared to compound 5. Closest H₃R ligand analogues in CHEMBL 24 [40] were identified by employing Morgan fingerprints [41] implemented in RDKit [42] nodes for KNIME [43] with a Tanimoto score of 0.53 for compound 5 and of 0.36 for compound 6 (Fig 4). The closest analogues were characterized as inverse agonists indicating the same mode of action for the newly identified compounds 5 and 6 [44,45]. According to Morgan fingerprints [41] both compounds significantly differ from CHEMBL1923737 whose docking pose was used for pharmacophore modeling (Table D in S1 File). This is in line with frequently observed scaffold hopping in pharmacophore screening campaigns [46]. The thiazole motif of compound 5 has recently also been incorporated in new lead findings for this receptor subtype [47]. Compound 6 is known as CHEMBL1433079 and was tested in different high throughput bioassays. However, none of the reported primary screen activities was further investigated hindering a proper assessment of the data.

The remaining compounds bound H₃R at a concentration of 10 μM less than 50% and were not considered for in-depth activity characterization (Fig 4). Compounds 1–4 and 7 represent a molecule class that does not carry a lipophilic moiety (e.g. ethyl, cyclopropyl) at the charged head group like in compound 5 and 6 indicating an important role of this structural feature. Compound 8 does carry such hydrophobic moiety at the positively charged amine but was also found to be inactive. Hence, we speculate that the methyl group might be too small to effectively fulfill this structural role.

**Conclusion**

In this study, we successfully applied a ligand-guided homology modeling workflow to H₃R. Therefore, 1000 homology models were generated and evaluated for allowing a charged interaction in ligand docking experiments. A structural analysis of best and worst performing models revealed an important conformation of the binding site residue E₅.₄₆ that is critical for proper ligand placement by the docking program. The best performing model was subsequently used in a virtual screening campaign and resulted in the identification of 2 novel H₃R ligands scaffolds with nanomolar affinity. Although successful, we do not claim that the best performing model is necessarily the most realistic one. However, we could show that many models were generated that allowed none or only few docking poses with the characteristic charged interaction. Thus, a single, easy-to-handle descriptor could be used to eliminate many low-quality homology models from further analysis.
**Experimental section**

**Preparation of ligand data**

The following workflow was conducted in KNIME [43] if not specified else. Histamine H₃ receptor (H₃R) ligand data was retrieved from Chembl 20 [40] database and filtered for

| ID | structure | Binding at 10 µM [%] | Kᵢ [nM] | Closest analogue in CHEMBL 24 |
|----|-----------|----------------------|---------|-------------------------------|
| 1  | ![Structure 1](image1.png) | 17.6 | - | - |
| 2  | ![Structure 2](image2.png) | 1.2 | - | - |
| 3  | ![Structure 3](image3.png) | -0.3 | - | - |
| 4  | ![Structure 4](image4.png) | 16.2 | - | - |
| 5  | ![Structure 5](image5.png) | 74.4 | 148.3 | a |
| 6  | ![Structure 6](image6.png) | 76.6 | 38.2 | b |
| 7  | ![Structure 7](image7.png) | 31.3 | - | - |
| 8  | ![Structure 8](image8.png) | 5.4 | - | - |

*Fig 4. In-vitro validation of virtual screening hits identified 2 novel nanomolar H₃R ligands.* Activity results of radioligand depletion assay against H₃R. Kᵢ data is presented as mean values calculated from at least three independent experiments, each performed in triplicates. aCHEMBL172076 with Tanimoto score of 0.53 when comparing with compound 5 using Morgan fingerprints. bCHEMBL180478 with Tanimoto score of 0.36 when comparing with compound 6 using Morgan fingerprints.

https://doi.org/10.1371/journal.pone.0218820.g004
molecular weight (≤ 500 Da), confidence score (= 9), standard activity type (Ki, Kd, IC50 or EC50), standard relation (=), standard activity value (≤ 10) and standard activity unit (nM). Ligands with unclarified stereo centers were removed with a combination of RDKit [42] and Indigo [48] nodes. If multiple activities were available for a single ligand, binding data (Ki, Kd) was preferred over functional data IC50 or EC50 and more recent data was preferred over older data. The literature of the remaining compounds was checked to remove agonists resulting in a final set of 632 inverse agonists. From this set 10 diverse inverse agonists (Table A in S1 File) were selected using the RDKit diversity picker based on MorganFeat fingerprints [41] (diameter = 4). This set was used for docking experiments to generate pharmacophores. Additionally, 100 diverse inverse agonists were selected for pharmacophore validation. Furthermore, the 100 diverse inverse agonists were used to generate decoys using the DUD-E decoy generator [39] for pharmacophore validation. The decoy set contains 3051 unique molecules.

3D coordinates of all molecules used in this study were generated and energetically minimized with the MMFF94s [49] force field using RDKit nodes [42]. Hydrogens were added, strong acids deprotonated and strong bases protonated by using the molecule wash function in MOE 2015 [24].

**Homology modeling**

The amino acid sequence of human H3R was retrieved from Uniprot [50] (Q9Y5N1) and employed for a homology model template search in the PDB [51] using the BLAST algorithm [52]. Structure files of the top ranked templates in the inactive conformation were used for an alignment in MOE 2015 [24]. Surprisingly, the crystal structure of H1R (3RZE [16]) did not show the highest sequence similarity to H3R. Also, the extracellular loop 2 (ECL2) close to the orthosteric binding pocket is not resolved in the H1R structure. Hence, homology modeling was performed with a multiple-template approach. MODELLER 9.15 [17] was used to generate 1000 homology models using H1R (3RZE [16]), muscarinic M2 receptor (M2R, 3UON [53]) and muscarinic M3 receptor (M3R, 4U15 [54]) as templates. Since ECL2 is not completely resolved in the H1R structure (3RZE), unresolved ECL2 parts were built by MODELLER solely based on M2R (3UON) and M3R (4U15). The sequence alignment as well as changed parameters of MODELLER functions can be found in the supporting information (Fig A and Table B in S1 File).

**Fig 5. Potential binding modes of active ligands are very similar.** Observed interaction of screening hits 5 (A) and 6 (B). Red arrows—hydrogen bond acceptors, green arrows—hydrogen bond donors, blue star—positive ionizable, yellow sphere—hydrophobic contact.

[https://doi.org/10.1371/journal.pone.0218820.g005](https://doi.org/10.1371/journal.pone.0218820.g005)
Docking experiments

A set of 9 inverse agonists [19] (Table C in S1 File) was chosen to guide the homology model selection and docked into all homology models using GOLD 5.2 [55] with default settings if not specified otherwise. The active site was defined by residues that are known from other aminergic GPCRs to be involved in ligand binding (D\textsubscript{3.32}, Y\textsubscript{3.33}, Y\textsubscript{4.56}, E\textsubscript{5.46}, W\textsubscript{6.48}, Y\textsubscript{6.51} and P\textsubscript{7.39}) [11]. 10 conformations were generated per molecule with the genetic algorithm set to 'Library Screening'. Early termination was disabled resulting in 90 conformations per homology model. Docking results were analyzed for ionic interaction between the ligand and D\textsubscript{3.32} that is characteristic for aminergic GPCRs [11]. Less or equal than 6 Å between the carbon atom of the carboxyl group of D\textsubscript{3.32} and the positively charged amine of the ligand was considered to be sufficient for ionic interaction. Docking and scoring have been performed to twice to control for variation introduced by the docking algorithm (Fig B in S1 File).

Homology model evaluation

10 best and 10 worst performing models were tested for geometric errors like phi-psi outliers and heavy atom clashes in MOE 2015 [24] as well as with homology modeling evaluation programs including VERIFY 3D [25], ERRAT [26] and PROVE [27]. No statistically significant difference was found (Fig C in S1 File).

Pharmacophore generation

The 10 diverse H\textsubscript{3}R inverse agonists generated as described above were docked into the selected homology model using GOLD 5.2 [55] with default settings if not specified otherwise. The active site was defined by residues that are known from other aminergic GPCRs to be involved in ligand binding (D\textsubscript{3.32}, Y\textsubscript{3.33}, Y\textsubscript{4.56}, E\textsubscript{5.46}, W\textsubscript{6.48}, Y\textsubscript{6.51} and P\textsubscript{7.39}) [11]. 10 conformations were generated per molecules with flip ring corners, flip pyramidal N and generate diverse solutions settings enabled and early termination setting disabled. Protein HBond constraints with a constraint weight of 10 and a minimum H-bond geometry weight of 0.005 were added to focus on conformations involving hydrogen bonds to carboxyl oxygens of D\textsubscript{3.32} and E\textsubscript{5.46}, since all docked ligands contain a positively charged group that should interact with negatively charged carboxyl-group of D\textsubscript{3.32} or E\textsubscript{5.42}. Docking results were analyzed in LigandScout 3.12 [56] for interactions explaining the structure-activity relationship. Selected complexes were minimized using Szybki 1.8.0.1 [38] with the MMFF94s forcefield and the Poisson-Boltzmann model. Sidechains within 10 Å were set flexible to allow adaption of the binding site residues to the docked ligand. LigandScout 3.12 was used to generate pharmacophores of the minimized complexes. Default pharmacophores generated with LigandScout 3.12 were optimized against a set of 100 diverse active inverse agonists and 3051 decoys by removing features or increasing the tolerance radius of selected features if supported by the structure activity relationship. Three pharmacophores were found to successfully discriminate between actives and decoys according to receiver operating characteristic curves (Fig E in S1 File).

Virtual screening and selection

The three selected pharmacophores were employed to screen a library of 1464080 molecules (Enamine Ltd., Kyiv, Ukraine, www.enamine.net) using LigandScout 3.12 [56] resulting in 15965 hits. These hits were redocked into the respective minimized model using GOLD 5.2 with default settings if not specified otherwise. The active site was defined by residues that are known from other aminergic GPCRs to be involved in ligand binding (D\textsubscript{3.32}, Y\textsubscript{3.33}, Y\textsubscript{4.56}, E\textsubscript{5.46}, W\textsubscript{6.48}, Y\textsubscript{6.51} and P\textsubscript{7.39}) [11]. 10 conformations were generated per molecules with flip ring
corners, flip pyramidal N and generate diverse solutions settings enabled. The redocked poses were scored to match the features of the respective pharmacophore model resulting in 73 hits. This set was visually inspected, and 10 molecules were selected for purchase. Ordered compounds were analyzed for purity with LC-MS leading to exclusion of 2 molecules from further analysis. The 8 remaining molecules possess purities of at least 95% and were tested in-vitro for activity against H₃R (Table E in S1 File).

**In-vitro experiments**

Radioligand depletion assays were performed as described previously using crude hH₃R membrane extracts obtained from HEK-293 cells stably expressing the hH₃R [15,57]. Briefly, crude membrane extracts were incubated with various concentrations of test ligands (between 0.01 nM and 100 μM) and [3H]-N-alpha-methylhistamine. Bound radioligand were harvested through GF/B filters and measured using liquid scintillation counting. Data analysis were performed with GraphPad Prism 6 using non-linear regression. The Ki values for each experiment were obtained according to Cheng-Prusoff and converted to pKi values to allow statistical analysis. Mean values were calculated from at least three independent experiments, each performed in triplicates (Table E in S1 File).

**Supporting information**

S1 File. PDF File with used molecular structures as well as more detailed parameters and results. (PDF)

**Acknowledgments**

We thank Gina Alpert for excellent technical assistance. We would like to thank the Elsa-Neumann-Foundation for financial support of DS.

**Author Contributions**

**Conceptualization:** David Schaller, Gerhard Wolber.

**Investigation:** David Schaller, Stefanie Hagenow, Holger Stark.

**Methodology:** David Schaller.

**Resources:** Gerhard Wolber.

**Software:** David Schaller, Gerhard Wolber.

**Writing – original draft:** David Schaller, Holger Stark.

**Writing – review & editing:** Holger Stark, Gerhard Wolber.

**References**

1. Lavecchia A, Giovanni C. Virtual Screening Strategies in Drug Discovery: A Critical Review. Curr Med Chem. 2013; 20: 2839–2860. https://doi.org/10.2174/09298673113209990001 PMID: 23651302

2. Ripphausen P, Nisius B, Peltason L, Bajorath J. Quo Vadis, Virtual Screening? A Comprehensive Survey of Prospective Applications. J Med Chem. 2010; 53: 8461–8467. https://doi.org/10.1021/jm101020z PMID: 20929257

3. Schmidt T, Bergner A, Schwede T. Modelling three-dimensional protein structures for applications in drug design. Drug Discov Today. 2014; 19: 890–897. https://doi.org/10.1016/j.drudis.2013.10.027 PMID: 24216321
4. Rodríguez D, Ranganathan A, Carlsson J. Strategies for improved modeling of GPCR-drug complexes: Blind predictions of serotonin receptors bound to ergotamine. J Chem Inf Model. 2014; 54: 2004–2021. https://doi.org/10.1021/ci5002235 PMID: 25030302

5. Kolaczkowski M, Bucki A, Feder M, Pawłowski M. Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening. J Chem Inf Model. 2013; 53: 638–648. https://doi.org/10.1021/ci300413h PMID: 23398329

6. Freyd T, Warszycyki D, Mordalski S, Bojarski AJ, Sylte I, Gabrielsen M. Ligand-guided homology modeling of the GABAB2 subunit of the GABAB receptor. PLoS One. 2017; 12: e0173889. https://doi.org/10.1371/journal.pone.0173889 PMID: 28323850

7. Evers A, Klebe G. Successful Virtual Screening for a Submicro molar Antagoni st of the Neurokini n-1 Receptor Based on a Ligand-Suppor ted Homology Model. J Med Chem. 2004; 47: 5381–5392. https://doi.org/10.1021/jm0311487 PMID: 15481976

8. Warren GL, Andrews CW, Capelli A-M, Clarke B, LaLonde J, Lambert MH, et al. A critical assessmen t of docking programs and scoring functions. J Med Chem. 2006; 49: 5912–31. https://doi.org/10.1021/jm050362n PMID: 17004707

9. Teague SJ. Implications of protein flexibili ty for drug discovery. Nat Rev Drug Discov. 2003; 2: 527–541. https://doi.org/10.1038/nrd1129 PMID: 12838268

10. Ragland DA, Whitfield TW, Lee S-K, Swanson R, Zeldovich KB, Kurt-Yilmaz N, et al. Elucidating the Interdependence of Drug Resistance from Combinations of Mutations. J Chem Theory Comput. 2017; 13: 5671–5682. https://doi.org/10.1021/acs.jctc.7b00540

11. Michino M, Beuming T, Donthamsetti P, Newman AH, Javitch JA, Shi L. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Pharmacol Rev. 2015; 67: 198–213. https://doi.org/10.1124/pr.114.009944 PMID: 25527701

12. Nikolik K, Agbaba D, Stark H. Pharmacophore modeling, drug design and virtual screening on multi-targeti ng procatagonc agents approaching histaminergic pathways. J Taiwan Inst Chem Eng. 2015; 46: 15–29. https://doi.org/10.1016/j.jtice.2014.09.017

13. Berlin M, Boyce CW, De Lera Ruiz M. Histamine H3 receptor as a drug discovery target. J Med Chem. 2011; 54: 26–53. https://doi.org/10.1021/jm100064d PMID: 21062081

14. Khanfar MA, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H. Multiple Targeti ng Approaches on Histamine H3 Receptor Antagonists. Front Neurosci. 2016; 10: 1–17. https://doi.org/10.3389/fnins.2016.00001d

15. Schaller D, Hagenow S, Alpert G, Naß A, Schulz R, Bermudez M, et al. Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. ACS Med Chem Lett. 2017; 8: 648–53. https://doi.org/10.1021/acsmedchemlett.7b00118 PMID: 28626527

16. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011; 475: 65–70. https://doi.org/10.1038/nature10236 PMID: 21697825

17. Webb B, Salì A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinforma. 2016; 54: 5.6.1–5.6.37. https://doi.org/10.1002/cpbi.3 PMID: 27322406

18. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14: 33–8, 27–8. https://doi.org/10.1016/0263-7855(96)00018-5 PMID: 8744570

19. Berlin M, Lee YJ, Boyce CW, Wang Y, Aslanian R, McCormick KD, et al. Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists. Bioorg Med Chem Lett. 2010; 20: 2359–64. https://doi.org/10.1016/j.bmcl.2010.01.121 PMID: 20188550

20. Ballesteros JA, Weinstein H. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neu ros. 1995; 25: 366–428. https://doi.org/10.1016/S1043-9471(05)80049-7

21. Chien EYT, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science. 2010; 330: 1091–5. https://doi.org/10.1126/science.1197410 PMID: 21097933

22. Thal DM, Sun B, Feng D, Nawaratevane V, Leach K, Felder CC, et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature. 2016; 531: 335–340. https://doi.org/10.1038/nature17188 PMID: 26958838

23. Stauss DP, Strachan RT, Manglik A, Pani B, Kahsai AW, Kim TH, et al. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature. 2016; 535: 448–52. https://doi.org/10.1038/nature18636 PMID: 27409812

24. Chemical Computing Group Inc. Molecular Operating Environment (MOE). Montreal, QC, Canada; 2015. pp. 1010 Sherbooke St. West, Suite #910.
25. Lüthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature. 1992; 356: 83–5. https://doi.org/10.1038/356083a0 PMID: 1538787

26. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993; 2: 1511–9. https://doi.org/10.1002/pro.5560020916 PMID: 8401235

27. Pontius J, Richelle J, Wodak SJ. Deviations from standard atomic volumes as a quality measure for protein crystal structures. J Mol Biol. 1996; 264: 121–36. https://doi.org/10.1006/jmbi.1996.0628 PMID: 8950272

28. Uveges AJ, Kowal D, Zhang Y, Spangler TB, Dunlop J, Semus S, et al. The role of transmembrane helix 5 in agonist binding to the human H3 receptor. J Pharmacol Exp Ther. 2002; 301: 451–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/11961043 https://doi.org/10.1124/jpet.301.2.451 PMID: 11961043

29. Kiss R, Kereszi GM. Structure-based discovery and binding site analysis of histamine receptor ligands. Expert Opin Drug Discov. Taylor & Francis; 2016; 11: 1165–1185. https://doi.org/10.1080/17460441.2016.1245288 PMID: 27704986

30. Kooistra AJ, Kuhne S, de Esch IJP, Leurs R, de Graaf C. A structural chemogenomics analysis of amnergicGPCRs: lessons for histamine receptor ligand design. Br J Pharmacol. 2013; 170: 101–126. https://doi.org/10.1111/bph.12248 PMID: 23713847

31. Becknell NC, Lyons JA, Aimone LD, Gruner JA, Mathiasen JR, Raddatz R, et al. Synthesis and evaluation of pyridone-phenoxypyropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2011; 21: 7076–80. https://doi.org/10.1016/j.bmcl.2011.09.091 PMID: 22014551

32. Wager TT, Pettersen BA, Schmidt AW, Spracklin DK, Mente S, Butler TW, et al. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluorodimethylpyrrolidiny1]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluorodimethylpyrrolidiny1]phenyl]-(N-2-methylpropyl)cyclobuta. J Med Chem. 2011; 54: 7602–20. https://doi.org/10.1021/jm200939b PMID: 21928839

33. Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukaszczyk U, Nagorny R, et al. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I). Bioorganic Med Chem Lett. Elsevier Ltd; 2013; 23: 3416–3420. https://doi.org/10.1016/j.bmcl.2013.03.080 PMID: 23591110

34. Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, Stricker-Krongrad A, et al. Investigation of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett. 2010; 20: 6246–9. https://doi.org/10.1016/j.bmcl.2010.08.099 PMID: 20833043

35. Watanabe M, Kazuta Y, Hayashi H, Yamada S, Matsuda A, Shuto S. Sterechemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolycyclopropane structure. J Med Chem. 2006; 49: 5587–96. https://doi.org/10.1021/jm0603318 PMID: 16942032

36. Moguilevsky N, Varsalona F, Guillaume JP, Noyer M, Gillard M, Daliers J, et al. Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H1 histamine receptor stably expressed in CHO cells. J Recept Signal Transduct Res. 2015; 9: 91–102. https://doi.org/10.3109/10799899509045210 PMID: 8903934

37. Bruysters M, Pertz HH, Teunissen A, Bakker RA, Gillard M, Chatelain P, et al. Mutational analysis of the histamine H1-receptor binding pocket of histaprodifen. J Med Chem. 2004; 47: 56–63. https://doi.org/10.1021/jm0303376

38. SZYBKI 1.8.0.1: OpenEye Scientific Software, Santa Fe, NM; http://www.eyesopen.com.

39. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. J Med Chem. 2012; 55: 6582–6594. https://doi.org/10.1021/jm300687e PMID: 22716043

40. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al. The ChEMBL bioactivity database: An update. Nucleic Acids Res. 2014; 42. https://doi.org/10.1093/nar/gkt1031 PMID: 24214965

41. Rogers D, Hahn M. Extended-connectivity fingerprints. J Chem Inf Model. 2010; 50: 742–754. https://doi.org/10.1021/ci100059t PMID: 20426451

42. RDKit: Open-source cheminformatics; http://www.rdkit.org.

43. Berthold MR, Cebron N, Dill F, Gabriel TR, Kötter T, Meinl T, et al. KNIME: The Konstanz Information Miner. 2008. pp. 319–326. https://doi.org/10.1007/978-3-540-78246-9_38

44. Zaragoza F, Stephens H, Peschke B, Rimvall K. 2-(4-Alkylpiperazin-1-yl)quinolines as a New Class of Imidazole-Free Histamine H3 Receptor Antagonists. J Med Chem. 2005; 48: 306–311. https://doi.org/10.1021/jm040873u PMID: 15634025
45. Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, et al. Pre-clinical characterization of aryloxyypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development. Bioorg Med Chem Lett. 2010; 20: 4210–4214. https://doi.org/10.1016/j.bmcl.2010.05.041 PMID: 20561786

46. Schneider Neidhart, Giller Schmid. “Scaffold-Hopping” by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew Chem Int Ed Engl. 1999; 38: 2894–2896. Available: http://www.ncbi.nlm.nih.gov/pubmed/10540384 PMID: 10540384

47. Khanfar MA, Reiner D, Hagenow S, Stark H. Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3 R ligands. Bioorg Med Chem. Elsevier; 2018; 26: 4034–4046. https://doi.org/10.1016/j.bmc.2018.06.028 PMID: 29960729

48. Pavlov D, Rybaikin M, Karulin B, Kozhevnikov M, Saveliev A, Churinov A. Indigo: universal cheminformatics API. J Cheminform. 2011; 3: P4. https://doi.org/10.1186/1758-2946-3-S1-P4

49. Halgren TA. MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem. 1999; 20: 720–729. https://doi.org/10.1002/(SICI)1096-987X(19990520)20:7<720::AID-JCC7>3.0.C0;2-X

50. Consortium UniProt. UniProt: a hub for protein information. Nucleic Acids Res. 2015; 43: D204–12. https://doi.org/10.1093/nar/gku989 PMID: 25348405

51. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28: 235–42. https://doi.org/10.1093/nar/28.1.235 PMID: 10592235

52. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990; 215: 403–410. https://doi.org/10.1016/S0022-2836(05)80360-2 PMID: 2231712

53. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature. 2012; 482: 547–51. https://doi.org/10.1038/nature10753 PMID: 22278061

54. Thorsen TS, Matt R, Weis WI, Koblika BK. Modified T4 Lysozyme Fusion Proteins Facilitate G Protein-Coupled Receptor Crystallography. Structure. 2014; 22: 1657–64. https://doi.org/10.1016/j.str.2014.08.002 PMID: 25450769

55. Cole J, Willem M, Nissink J, Taylor R. Protein-Ligand Docking and Virtual Screening with GOLD. In: Alvarez J, Shoichet B, editors. Virtual Screening in Drug Discovery. Boca Raton: Taylor & Francis CRC Press; 2005. pp. 379–415. https://doi.org/10.1201/9781420028775.ch15

56. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005; 45: 160–9. https://doi.org/10.1021/ci049885e PMID: 15667141

57. Kottke T, Sander K, Weizel L, Schneider EH, Seifert R, Stark H. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands. Eur J Pharmacol. 2011; 654: 200–8. https://doi.org/10.1016/j.ejphar.2010.12.033 PMID: 21237145